ASX Announcements

Phase 3 trial of trofinetide in Rett syndrome commences
Neuren Corporate Presentation, October 2019
Appendix 4C - quarterly
FDA grants Orphan Drug designation for NNZ-2591 in Phelan-McDermid and Pitt Hopkins syndromes
Pause in Trading
FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
Neuren approaching key milestones in Q4 2019
Neuren advances pipeline for neurodevelopmental disorders
Half Yearly Report and Accounts
New patent granted for Neuren's NNZ-2591 in Japan